Scribe Therapeutics Inc. (NASDAQ: SCTX) is a Healthcare company (Biotechnology) with a market capitalization of $255M. The Maz Rating grades it against the other companies in its sector.
Scribe Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.77, Scribe Therapeutics Inc. trades at 44.0x sales and 2.4x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $129M. It runs a gross margin of 73.3%, an operating margin of -564.8% and a net margin of -582.1%. It shows return on equity of -238.9%, return on invested capital of -21.6% and a free cash flow yield of -5.1%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 4.72. Over the past 52 weeks the share price ranged from $13.50 to $39.60, with a beta of 0.00.
Scribe Therapeutics Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.